Circulate Health, Inc. — SEC Form D Filing

Circulate Health, Inc. filed an SEC Form D on January 9, 2026, reporting $13.00M raised in Health & Wellness.

Form D filing details

Filing
SEC Form D
Filing date
January 9, 2026
Amount reported
$13.00M
Industry
Health & Wellness
Headquarters
Novato, United States
Website
https://www.circulate.health/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Age is the primary risk factor for many diseases and health issues, leading to significant healthcare costs and impacting quality of life.

Solution

Circulate Health offers Therapeutic Plasma Exchange (TPE), an evidence-based treatment that removes age-accelerating and disease-causing substances from the bloodstream, helping patients live healthier and longer.

Verdict

Investors backed a niche, high-cost therapy with a significant potential market, signaling implicit trust in the early clinical efficacy and the company's ability to navigate regulatory and ethical hurdles. This cleared because of the plausible high-value intervention for an undeniable health problem, not because of a proven scalable distribution model. The upside was limited by the inherent difficulty and cost structrure of scaling a medical procedure, contrasting with more straightforward pharmaceutical or device plays.

Source: SEC EDGAR Form D filing